Neuland Laboratories' Q4 FY 2025-26 Quarterly Results

Result Summary

• Neuland Laboratories Ltd reported a 76.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 134.9%.
• Its expenses for the quarter were up by 27.4% QoQ and 69.0% YoY.
• The net profit increased 424.2% QoQ and increased 664.7% YoY.
• The earnings per share (EPS) of Neuland Laboratories Ltd stood at 165.76 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Neuland Laboratories Ltd is a prominent player in the pharmaceutical industry, primarily focusing on the manufacturing of active pharmaceutical ingredients (APIs). The company is known for its expertise in complex chemistry and its ability to deliver high-quality products, which are integral components in the formulation of medicines. Neuland Laboratories has a strong reputation for its research and development capabilities and its commitment to maintaining high standards of compliance with international regulatory requirements. The company operates in a competitive market with a global footprint, catering to various geographies with its wide range of API offerings. As of the latest available information, there are no specific recent major developments disclosed for Neuland Laboratories.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Neuland Laboratories reported a total income of ₹788.71 crores, marking a significant increase from ₹447.76 crores in the third quarter of the same fiscal year (Q3FY26). This represents a quarter-over-quarter (QoQ) growth rate of 76.1%. When compared to the corresponding quarter in the previous fiscal year (Q4FY25), where the total income was ₹335.82 crores, the year-over-year (YoY) growth rate is an impressive 134.9%. This substantial increase in revenue reflects the company's robust performance in generating sales and possibly expanding market reach during this period.

Profitability

Neuland Laboratories demonstrated a notable enhancement in profitability during Q4FY26. The company's profit before tax (PBT) surged to ₹287.49 crores, a significant rise from ₹54.48 crores in Q3FY26. This translates to a remarkable QoQ increase of 427.7%. The YoY comparison shows an even more substantial growth of 631.5%, up from ₹39.30 crores in Q4FY25. After accounting for taxes, the profit after tax (PAT) for Q4FY26 was ₹212.67 crores, which was a substantial increase from ₹40.57 crores in the previous quarter, representing a 424.2% QoQ rise. Compared to the same quarter last year, where the PAT was ₹27.81 crores, the YoY growth stands at 664.7%. This exceptional growth in profitability is further reflected in the earnings per share (EPS), which increased from ₹31.62 in Q3FY26 to ₹165.76 in Q4FY26, a QoQ growth of 424.2%, and a YoY surge of 664.9% from ₹21.67 in Q4FY25.

Operating Metrics

The total expenses for Neuland Laboratories in Q4FY26 amounted to ₹501.22 crores, rising from ₹393.29 crores in Q3FY26, which indicates a QoQ increase of 27.4%. When compared to Q4FY25, where the total expenses were ₹296.53 crores, the YoY increase is 69.0%. This rise in expenses is accompanied by a corresponding increase in revenue, suggesting efficient cost management in relation to revenue growth. The tax expense for Q4FY26 was ₹74.82 crores, compared to ₹13.90 crores in Q3FY26, marking a QoQ rise of 438.3%. On a YoY basis, this represents a 551.2% increase from ₹11.49 crores in Q4FY25. The financial data indicates a significant growth trajectory in both revenue and profits, with a corresponding increase in tax obligations.